ScholarIQanswers from OpenAlex & ORCID
Alberto Chiappori
ResearcherPublications, citations & collaboration network
Alberto Chiappori is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Alberto Chiappori have?
ScholarIQindexed works
Alberto Chiappori has 257 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Alberto Chiappori have?
ScholarIQcitation count
Alberto Chiappori has 16,930 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Alberto Chiappori?
ScholarIQh-index
Alberto Chiappori has an h-index of 49 in OpenAlex.
What is the i10-index of Alberto Chiappori?
ScholarIQi10-index
Alberto Chiappori has an i10-index of 105 in OpenAlex.
What is the ORCID of Alberto Chiappori?
ScholarIQorcid
The ORCID for Alberto Chiappori is on the source record.
What is the OpenAlex record for Alberto Chiappori?
ScholarIQopenalex
The OpenAlex for Alberto Chiappori is on the source record.
What are the most-cited papers on Alberto Chiappori?
ScholarIQmost cited works
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely, Alberto Chiappori, Howard West, Michele C. Azada, Peter N. Morcos, Ruey-min Lee, Linta Garcia, Li Yu, Frédéric Boisserie, Laura Di Laurenzio, Sophie Golding, Jotaro Sato, Shumpei Yokoyama, Tomohiro Tanaka, Sai‐Hong Ignatius Ou
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel, Gregory J. Riely, Jeremy Cetnar, Howard West, D. Ross Camidge, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Ali Zeaiter, Walter Bordogna, Bogdana Balas, Óscar Puig, Volkmar Henschel, Sai‐Hong Ignatius Ou
Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer
Scott Antonia, Noweeda Mirza, Ingo Fricke, Alberto Chiappori, Patricia Thompson, Nicholas S. G. Williams, Gerold Bepler, George R. Simon, William E. Janssen, Ji‐Hyun Lee, Kerstin Menander, Sunil Chada, Dmitry I. Gabrilovich